Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
January 04, 2024 08:00 ET
|
Quanta Therapeutics, Inc.
QTX3034, G12D-preferring multi-KRAS inhibitor, IND received clearance by US FDA to begin Phase 1 study; planned for 1Q24; and other pipeline updates
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
December 12, 2023 08:00 ET
|
Immuneering Corporation
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference
October 11, 2023 12:00 ET
|
Quanta Therapeutics, Inc.
The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.
Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
June 29, 2023 08:29 ET
|
Pasithea
PALO ALTO, Calif. and MIAMI, June 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
March 14, 2023 16:30 ET
|
Immuneering Corporation
Demonstrates ability to identify patient populations that may benefit from IMM-1-104 treatment Biomarker discovery and clinical translation supports patient selection in ongoing Phase 1/2a clinical...
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 06, 2023 16:05 ET
|
Immuneering Corporation
First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected...
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
March 05, 2023 18:30 ET
|
Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...